Taihe Biotechnology cooperates with the pre-listing auction and the underwriting price is tentatively set at 105.6 yuan

Li Shiren, Chairman of Taihe Biotechnology (file photo)

[Reporter Chen Yongji/Taipei Report] Taihe Biotech Pharmaceuticals (6467) cooperated with the pre-market public underwriting and auctioned 5,100 tickets, with a minimum bidding price of 88 yuan, the highest number of bids was 669, and the tentative underwriting price per share was 105.6 yuan. The bidding period is from October 2nd to 6th, and public subscription will be processed from October 7th to 12th. It is expected to be listed on October 20th. Since the stock price of Taihexing Cabinet is currently about 240 yuan, it means that if you win one ticket through public subscription, you can make double the profit immediately.

Taihe focuses on the independent research and development of transepithelial drug delivery systems (TDS) and improves existing drug ingredients into new transdermal and transmucosal dosage forms. Its main product, BEQIA, is the world's first anti-thrombotic orally dissolving film containing Apixaban designed specifically for people with swallowing difficulties. It can be administered without drinking water or swallowing tablets, targeting the elderly, those with difficulty swallowing and those who require long-term anti-thrombotic treatment.

The product was resubmitted to the USFDA on June 19 this year. The information is complete and meets regulatory requirements. It has officially entered the 10-month PDUFA review period. April 22, 2027 is the target date for review completion, and it is expected to obtain a US drug certificate. The European part will complete the Day 121 critical list response in July 2026, moving towards the CHMP final review opinion (Day 210) and EC approval. It is also expected to obtain EU marketing authorization in the fourth quarter of 2026.

At the same time, Taihe adopts a licensing strategy of "original and non-original dual-track parallel". Currently, Taihe has signed NDAs and continued negotiations with dozens of pharmaceutical companies in Europe, the United States, New Zealand, Australia, Latin America and other regions. Many large multinational pharmaceutical companies have entered the substantive negotiation stage with BD representatives in various regions.